The approval means that data on the drug’s effects have been reviewed and prove that the drug provides benefits that outweigh its known and potential risks for the intended population.
The development comes barely six months after the World Health Organisation (WHO) recommended the drug as an additional HIV prevention choice as part of combination HIV-prevention approaches.
